Oncotarget

Meta-Analysis:

Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies

Keming Yang, Andrew Marley, Huilin Tang, Yiqing Song, Jean Y. Tang and Jiali Han _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:75411-75417. https://doi.org/10.18632/oncotarget.20034

Metrics: PDF 745 views  |   HTML 1703 views  |   ?  


Abstract

Keming Yang1, Andrew Marley1, Huilin Tang1, Yiqing Song1, Jean Y. Tang2 and Jiali Han1

1Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN 46202-2872, USA

2Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94063, USA

Correspondence to:

Jiali Han, email: jialhan@iu.edu

Keywords: statins, non-melanoma skin cancer, meta-analysis

Received: June 26, 2017     Accepted: July 26, 2017     Published: August 08, 2017

ABSTRACT

Background: Existing evidence of the association between statin use and non-melanoma skin cancer (NMSC) risk has been inconsistent.

Objective: To maximize statistical power to synthesize prospective evidence on this relationship.

Materials and Methods: PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrial.gov were systematically searched up to December 11, 2016. A random-effects meta-analysis was conducted to calculate summary estimates.

Results: Our meta-analysis of 14 randomized controlled trials (RCTs) including 63,157 subjects showed no significant association between statin use and NMSC risk (RR = 1.09, 95%CI = 0.85–1.39). However, meta-analysis of four observational studies including 1,528,215 participants showed significantly increased risk of NMSC among statin users compared to non-users (RR = 1.11, 95%CI = 1.02–1.22). Furthermore, ever using lipophilic statins (RR = 1.14, 95%CI = 1.04–1.24) or lower-potency statins (RR = 1.14, 95%CI = 1.03–1.26), as well as usage of any statin longer than one year (RR = 1.14, 95%CI = 1.09–1.18) were significantly associated with increased NMSC risk based on observational studies.

Conclusions: Evidence from observational studies supported an association between statin use and increased NMSC risk. This finding should be interpreted with caution due to modest number of included studies, possible between-study heterogeneity and inherent limitations of observational studies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20034